MX2020013525A - Motivo de interaccion amiloide general. - Google Patents
Motivo de interaccion amiloide general.Info
- Publication number
- MX2020013525A MX2020013525A MX2020013525A MX2020013525A MX2020013525A MX 2020013525 A MX2020013525 A MX 2020013525A MX 2020013525 A MX2020013525 A MX 2020013525A MX 2020013525 A MX2020013525 A MX 2020013525A MX 2020013525 A MX2020013525 A MX 2020013525A
- Authority
- MX
- Mexico
- Prior art keywords
- amyloid
- gaim
- methods
- variants
- fusion proteins
- Prior art date
Links
- 230000003993 interaction Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 2
- 241001515965 unidentified phage Species 0.000 abstract 2
- 101710192393 Attachment protein G3P Proteins 0.000 abstract 1
- 101710179596 Gene 3 protein Proteins 0.000 abstract 1
- 230000006933 amyloid-beta aggregation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685757P | 2018-06-15 | 2018-06-15 | |
| US201862749499P | 2018-10-23 | 2018-10-23 | |
| PCT/US2019/037179 WO2019241628A1 (en) | 2018-06-15 | 2019-06-14 | General amyloid interaction motif (gaim) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013525A true MX2020013525A (es) | 2021-02-26 |
Family
ID=67263052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013525A MX2020013525A (es) | 2018-06-15 | 2019-06-14 | Motivo de interaccion amiloide general. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11692017B2 (https=) |
| EP (2) | EP3806884B1 (https=) |
| JP (1) | JP7549536B2 (https=) |
| CN (1) | CN112672755A (https=) |
| AU (1) | AU2019287623B2 (https=) |
| BR (1) | BR112020025111A2 (https=) |
| ES (1) | ES2960493T3 (https=) |
| IL (1) | IL279333B2 (https=) |
| MX (1) | MX2020013525A (https=) |
| PL (1) | PL3806884T3 (https=) |
| SG (1) | SG11202012091WA (https=) |
| WO (1) | WO2019241628A1 (https=) |
| ZA (1) | ZA202100071B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3806884B1 (en) * | 2018-06-15 | 2023-08-02 | Amyl Therapeutics | General amyloid interaction motif (gaim) |
| JP7505713B2 (ja) * | 2019-02-22 | 2024-06-25 | ロヨラ メリーマウント ユニバーシティ | アミロイドペプチドバリアント |
| CN120641092A (zh) | 2022-12-02 | 2025-09-12 | 阿尔泽恩股份有限公司 | 用于用曲米沙特治疗神经变性病症的方法 |
| CN117343200B (zh) * | 2023-12-04 | 2024-01-30 | 北京质肽生物医药科技有限公司 | 一种包含淀粉样核心多肽的融合蛋白、制备方法及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US8022270B2 (en) | 2000-07-31 | 2011-09-20 | Biolex Therapeutics, Inc. | Expression of biologically active polypeptides in duckweed |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| JP2007531707A (ja) | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ， インコーポレイテッド | ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変 |
| CN114748605A (zh) * | 2011-11-29 | 2022-07-15 | 普罗克拉拉生物科学股份有限公司 | 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途 |
| CN104870008B (zh) | 2012-10-02 | 2019-10-01 | 普罗克拉拉生物科学股份有限公司 | 噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途 |
| KR20160010618A (ko) | 2013-05-28 | 2016-01-27 | 뉴로페이지 파마슈티컬즈, 인크. | 감소된 면역원성을 갖는 개질된 박테리오파아지 g3p 아미노산 서열을 포함하는 폴리펩티드 |
| PL3227313T3 (pl) | 2014-12-03 | 2022-05-09 | Proclara Biosciences, Inc. | Polipeptydy zawierające zmodyfikowaną sekwencję aminokwasową bakteriofaga g3p pozbawioną sygnału glikozylacji |
| EP3806884B1 (en) * | 2018-06-15 | 2023-08-02 | Amyl Therapeutics | General amyloid interaction motif (gaim) |
-
2019
- 2019-06-14 EP EP19739769.8A patent/EP3806884B1/en active Active
- 2019-06-14 MX MX2020013525A patent/MX2020013525A/es unknown
- 2019-06-14 AU AU2019287623A patent/AU2019287623B2/en active Active
- 2019-06-14 EP EP23188404.0A patent/EP4389154A3/en active Pending
- 2019-06-14 WO PCT/US2019/037179 patent/WO2019241628A1/en not_active Ceased
- 2019-06-14 SG SG11202012091WA patent/SG11202012091WA/en unknown
- 2019-06-14 JP JP2020569166A patent/JP7549536B2/ja active Active
- 2019-06-14 PL PL19739769.8T patent/PL3806884T3/pl unknown
- 2019-06-14 ES ES19739769T patent/ES2960493T3/es active Active
- 2019-06-14 BR BR112020025111-9A patent/BR112020025111A2/pt unknown
- 2019-06-14 CN CN201980049538.2A patent/CN112672755A/zh active Pending
- 2019-06-14 US US17/251,351 patent/US11692017B2/en active Active
-
2020
- 2020-12-09 IL IL279333A patent/IL279333B2/en unknown
-
2021
- 2021-01-05 ZA ZA2021/00071A patent/ZA202100071B/en unknown
-
2023
- 2023-05-19 US US18/320,697 patent/US12247055B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020025111A2 (pt) | 2021-04-06 |
| EP4389154A3 (en) | 2024-11-13 |
| IL279333B2 (en) | 2023-06-01 |
| CA3102841A1 (en) | 2019-12-19 |
| SG11202012091WA (en) | 2021-01-28 |
| US20210246179A1 (en) | 2021-08-12 |
| CN112672755A (zh) | 2021-04-16 |
| ES2960493T3 (es) | 2024-03-05 |
| EP3806884A1 (en) | 2021-04-21 |
| EP3806884C0 (en) | 2023-08-02 |
| ZA202100071B (en) | 2023-04-26 |
| US12247055B2 (en) | 2025-03-11 |
| EP4389154A2 (en) | 2024-06-26 |
| AU2019287623B2 (en) | 2024-11-07 |
| US11692017B2 (en) | 2023-07-04 |
| AU2019287623A1 (en) | 2021-01-07 |
| IL279333A (en) | 2021-01-31 |
| US20230279064A1 (en) | 2023-09-07 |
| JP7549536B2 (ja) | 2024-09-11 |
| WO2019241628A1 (en) | 2019-12-19 |
| JP2021527407A (ja) | 2021-10-14 |
| EP3806884B1 (en) | 2023-08-02 |
| PL3806884T3 (pl) | 2023-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013525A (es) | Motivo de interaccion amiloide general. | |
| CN109937252A (zh) | 重组dna聚合酶 | |
| JP2014193892A5 (https=) | ||
| JP2015212284A5 (https=) | ||
| AR047729A1 (es) | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| JOP20220043A1 (ar) | بروتين كابسيد vp1 معدل معزول من aav5 | |
| MX2020007882A (es) | Variantes fc con unión mejorada a fcrn y semivida prolongada. | |
| JP2019514367A5 (https=) | ||
| Takano et al. | Prefoldin prevents aggregation of α-synuclein | |
| JP2018531624A5 (https=) | ||
| CN110036108A (zh) | 一种细菌β-1,3-葡聚糖酶及其编码基因与应用 | |
| ES2601149T3 (es) | Productos génicos de expresión diferencial en tumores y su uso | |
| MX2021004714A (es) | Proteina cas9 modificada, y uso de la misma. | |
| CN109641937A (zh) | OsAO基因在提高水稻对水稻条纹病毒及水稻黑条矮缩病毒或其同科病毒抗性中的应用 | |
| JP2020517643A5 (https=) | ||
| JP2016537981A5 (https=) | ||
| BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. | |
| JP2019512693A5 (https=) | ||
| Boddapati et al. | Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP | |
| CN110049994A (zh) | 一种缀合物及其应用 | |
| MX2018003162A (es) | Variante en el numero de copias que genera resistencia a virus. | |
| EP1984013A4 (en) | CST II MODIFICATIONS FOR INCREASED PROTEIN EXPRESSION | |
| WO2008033451A3 (en) | Protein aggregation domains from prions and methods of use thereof | |
| JP2018508571A5 (https=) |